Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
- Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
- Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 100
- Registration Number
- NCT05766800
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC
- Conditions
- Interventions
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 61
- Registration Number
- NCT05765825
- Locations
- 🇨🇳
GuiZhou Provincial People's Hospital, Guiyang, China
🇨🇳Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China
🇨🇳Chongqing University cancer hospital, Chongqing, Chongqing, China
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC
- Conditions
- Interventions
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 374
- Registration Number
- NCT05756972
- Locations
- 🇨🇳
Medical Ethics Committee of Guangdong Provincial People's Hospital, Guangzhou, Guangdonng, China
Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 54
- Registration Number
- NCT05751187
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, China
Tiragolumab and Atezolizumab in Patients with Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Liza Villaruz, MD
- Target Recruit Count
- 3
- Registration Number
- NCT05746481
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Target Recruit Count
- 84
- Registration Number
- NCT05741021
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Imunon
- Target Recruit Count
- 50
- Registration Number
- NCT05739981
- Locations
- 🇺🇸
Johns Hopkins Medicine SKCCC, Baltimore, Maryland, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Correlation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy and the Preventive of Probiotics
- Conditions
- Interventions
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT05730777
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 28
- Registration Number
- NCT05726370
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Metastatic Hypopharyngeal Squamous Cell CarcinomaMetastatic Laryngeal Squamous Cell CarcinomaStage IV Laryngeal Cancer AJCC v8Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8Stage IV Hypopharyngeal Carcinoma AJCC v8Stage IV Lip and Oral Cavity Cancer AJCC v8Metastatic Head and Neck Squamous Cell CarcinomaMetastatic Oral Cavity Squamous Cell CarcinomaMetastatic Oropharyngeal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 290
- Registration Number
- NCT05721755
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Carle Physician Group-Effingham, Effingham, Illinois, United States
🇺🇸Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.